The molecular targets: GLP-1R and amylin receptor biology
The rationale for combining GLP-1 receptor agonism with amylin receptor activation rests on two receptor systems that suppress appetite through non-overlapping pathways. GLP-1 receptors engage both peripheral intestinal signals and hypothalamic circuits to reduce food intake and slow gastric emptying. Amylin receptors — heterodimeric complexes formed between the calcitonin receptor (CTR) and receptor activity-modifying proteins RAMP1, RAMP2, and RAMP3, generating AMY1, AMY2, and AMY3 receptor subtypes — act primarily via the area postrema and nucleus of the solitary tract in the brainstem to suppress food intake through distinct central circuits.
The complementarity of these two mechanisms is not incidental — it is the core scientific proposition for both amycretin and CagriSema. As described in the published literature on amylin receptor signalling, co-activation of GLP-1R and amylin receptors produces additive-to-synergistic weight reduction that neither agent achieves alone. This mechanistic logic is reinforced by the phase 2 CagriSema data: the combination produced approximately 15.6% weight loss at 32 weeks, compared to 5.1% for semaglutide alone and 8.7% for cagrilintide alone in the same trial population of 706 adults.
Amylin receptors are heterodimeric complexes of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3), generating three receptor subtypes: AMY1, AMY2, and AMY3. These receptors are expressed in the area postrema, nucleus of the solitary tract, hypothalamus, and — importantly for cardiovascular implications — in cardiac and vascular tissue.
The cardiovascular dimension of amylin receptor biology is an emerging area of interest. Amylin receptors expressed in cardiac and vascular tissue may provide direct cardioprotective effects beyond weight reduction — a signal flagged in preclinical and early clinical data reviewed in published literature on cardiovascular effects of amylin receptor activation. This has direct implications for regulatory strategy: the REDEFINE-CVOT trial, designed to enrol approximately 15,000 participants with obesity and established cardiovascular disease or high cardiovascular risk, will test whether CagriSema’s cardiovascular effects extend beyond those attributable to weight loss alone, following the precedent set by semaglutide’s SELECT cardiovascular outcomes trial.
Amylin receptors are heterodimeric complexes of the calcitonin receptor (CTR) with RAMP1, RAMP2, or RAMP3, generating AMY1, AMY2, and AMY3 receptor subtypes. These receptors are expressed in the area postrema and nucleus of the solitary tract, where they suppress food intake through CNS circuits that are distinct from those engaged by GLP-1 receptor activation.
Amycretin’s unimolecular architecture and clinical signals
Amycretin is a single peptide molecule engineered to simultaneously engage GLP-1 receptors and amylin receptors, a design that provides what Novo Nordisk’s patent filings describe as “synchronized receptor engagement and consistent stoichiometric receptor activation.” This unimolecular architecture is the defining pharmacological distinction between amycretin and CagriSema, and it has practical consequences for both pharmacokinetics and manufacturing.
The pharmacokinetic engineering of amycretin draws on fatty acid modifications that enable albumin binding — the same strategy used to extend the half-life of semaglutide — to achieve a profile compatible with once-weekly subcutaneous dosing. According to PatSnap’s patent intelligence platform, Novo Nordisk has filed multiple patent families covering these fatty acid-modified GLP-1/amylin co-agonist peptides, with filings spanning US, WO, and EP jurisdictions from 2023 to 2024.
“A unimolecular design ensures simultaneous pharmacokinetic exposure of both pharmacophores, avoiding differential clearance — a key advantage over fixed-dose combination therapies where the two components may be absorbed, distributed, and eliminated at different rates.”
The phase 1/2 clinical results for once-weekly subcutaneous amycretin are striking: approximately 22% mean body weight reduction at 36 weeks in adults with overweight or obesity, with improvements in glycaemic markers and lipid profiles. This is numerically comparable to CagriSema’s phase 3 results and substantially exceeds the approximately 15% weight loss observed with semaglutide monotherapy. The most common adverse events were gastrointestinal, consistent with the GLP-1/amylin class profile.
Novo Nordisk has also disclosed oral amycretin formulations in patent filings. Early phase 1/2 clinical results for oral amycretin showed up to approximately 13% mean body weight reduction over 12 weeks — a notable result for an oral peptide, given the bioavailability challenges that typically limit oral GLP-1 agents. The oral route may offer patient compliance advantages over subcutaneous injection, and according to PatSnap’s innovation intelligence platform, patent filings covering oral amycretin formulations describe stabilised peptide preparations with acceptable shelf-life profiles.
Amycretin is a unimolecular GLP-1/amylin receptor co-agonist developed by Novo Nordisk that demonstrated approximately 22% mean body weight reduction at 36 weeks in a phase 1/2 trial of once-weekly subcutaneous administration in adults with overweight or obesity. An oral formulation of amycretin showed up to approximately 13% mean body weight reduction over 12 weeks in early phase 1/2 clinical results.
Explore the full amycretin and GLP-1/amylin patent landscape with PatSnap Eureka’s AI-powered drug intelligence tools.
Search Amycretin Patents in PatSnap Eureka →CagriSema and the REDEFINE phase 3 program
CagriSema is a bimolecular combination of cagrilintide (a long-acting amylin analogue suitable for once-weekly subcutaneous administration) and semaglutide (the GLP-1 receptor agonist used in Ozempic and Wegovy), co-administered as a fixed-dose combination at 2.4 mg + 2.4 mg once-weekly. The REDEFINE phase 3 program represents the most advanced clinical evidence for GLP-1/amylin co-targeting in obesity to date.
REDEFINE 1, the pivotal trial in adults with obesity or overweight with weight-related comorbidities but without type 2 diabetes, enrolled 3,417 participants and demonstrated 22.7% mean body weight reduction at week 68 versus 2.3% for placebo. More than 40% of participants achieved 25% or greater weight loss — a threshold that had not previously been achieved in a phase 3 obesity trial with a once-weekly injectable. According to WHO estimates, obesity affects over 1 billion people globally, making the scale of the addressable market for these agents substantial.
The REDEFINE 2 phase 3 trial of CagriSema in adults with type 2 diabetes and obesity demonstrated approximately 15.7% mean body weight reduction at 68 weeks, with significant improvements in HbA1c. This is notably lower than the 22.7% observed in REDEFINE 1, consistent with the well-established pattern of attenuated weight loss in patients with type 2 diabetes across GLP-1 class agents.
The REDEFINE-CVOT trial extends the program into cardiovascular outcomes, designed to enrol approximately 15,000 participants with obesity and established cardiovascular disease or high cardiovascular risk. The trial will measure three-point major adverse cardiovascular events (MACE) as its primary endpoint, following the precedent established by the SELECT trial for semaglutide. Published research in journals such as New England Journal of Medicine has established that GLP-1 receptor agonists can reduce cardiovascular events independent of weight loss, and the amylin receptor’s expression in cardiac and vascular tissue raises the possibility of additive cardioprotective mechanisms with CagriSema.
The CagriSema REDEFINE 1 phase 3 trial enrolled 3,417 adults with obesity or overweight with weight-related comorbidities and demonstrated 22.7% mean body weight reduction at week 68 versus 2.3% for placebo, with more than 40% of participants achieving 25% or greater weight loss — the highest weight loss reported in a phase 3 obesity trial with a once-weekly injectable at the time of reporting.
Comparing the two strategies: efficacy, IP, and commercial positioning
The unimolecular versus bimolecular distinction between amycretin and CagriSema is more than a manufacturing consideration — it shapes the IP landscape, the regulatory path, and the commercial differentiation argument for each asset. Published analysis of Novo Nordisk’s obesity portfolio strategy has framed the question as whether these two programs represent competitive cannibalization within the same company or differentiated assets targeting distinct commercial segments.
From a pharmacological standpoint, the unimolecular design of amycretin ensures that both GLP-1R and amylin receptor agonist activity are delivered with identical pharmacokinetics — the same absorption, distribution, metabolism, and elimination profile for both pharmacophores. In a bimolecular combination such as CagriSema, cagrilintide and semaglutide are separate molecules with distinct pharmacokinetic profiles that are co-administered but not pharmacokinetically linked. Published drug design analysis notes that differential clearance of the two components in a combination therapy could result in variable receptor engagement ratios over the dosing interval — a theoretical concern that the unimolecular design of amycretin eliminates by construction.
A unimolecular co-agonist (such as amycretin) is a single peptide engineered to engage two receptor systems simultaneously, ensuring synchronized pharmacokinetics and consistent stoichiometric receptor activation. A bimolecular combination (such as CagriSema) co-administers two separate molecules — cagrilintide and semaglutide — that have distinct pharmacokinetic profiles and may be cleared at different rates.
On the IP side, Novo Nordisk’s patent portfolio covers both strategies with overlapping but distinct claim scopes. Patent filings for amycretin specifically claim the unimolecular co-agonist peptide structures, fatty acid modification strategies for albumin binding, oral formulations, and dosing regimens — with US, WO, and EP filings from 2023 to 2024. The CagriSema IP estate is more mature, with foundational cagrilintide patents dating to 2020 and combination method patents extending through 2023. According to the patent literature reviewed by PatSnap, Novo Nordisk has also filed on combinations of both GLP-1/amylin agents with SGLT2 inhibitors, suggesting a triple-combination development pathway is under active consideration.
In the CagriSema phase 2 dose-finding trial of 706 adults with overweight or obesity, the 2.4 mg cagrilintide + 2.4 mg semaglutide combination produced approximately 15.6% weight loss at 32 weeks, compared to 5.1% for semaglutide alone and 8.7% for cagrilintide alone in the same trial — demonstrating that the combination’s efficacy substantially exceeds the sum of its components.
Map Novo Nordisk’s full GLP-1/amylin patent portfolio — including amycretin and CagriSema IP families — using PatSnap Eureka’s drug intelligence tools.
Explore the Patent Landscape in PatSnap Eureka →Competitive landscape: where amycretin and CagriSema sit in the obesity pipeline
Both amycretin and CagriSema exist within a rapidly expanding obesity pharmacotherapy landscape that includes GLP-1 receptor agonists, GLP-1/GIP dual agonists (tirzepatide), GLP-1/glucagon dual agonists, and GLP-1/amylin combinations. The key competitive benchmark is tirzepatide (Eli Lilly’s GLP-1/GIP dual agonist), which demonstrated approximately 22% weight loss at 72 weeks in phase 3 trials — placing it in the same efficacy range as both amycretin and CagriSema at their respective trial endpoints.
Eli Lilly’s pipeline extends further with retatrutide, a GLP-1/GIP/glucagon triple agonist that demonstrated approximately 24% weight loss at 48 weeks in phase 2 trials — currently the highest weight loss reported for a pharmacological agent in a controlled clinical trial. According to research published by Nature and other peer-reviewed sources, the obesity drug development field is converging on the 20–25% weight loss range as the new efficacy benchmark, with differentiation increasingly dependent on cardiovascular outcomes, tolerability, oral bioavailability, and patient population-specific performance.
Within this context, Novo Nordisk’s dual strategy — advancing both CagriSema (with a mature phase 3 evidence base and a cardiovascular outcomes trial) and amycretin (with a potentially superior pharmacological architecture and an oral formulation in development) — positions the company to compete across multiple market segments. CagriSema’s phase 3 data and regulatory pathway make it the nearer-term commercial asset; amycretin’s unimolecular design and oral formulation represent longer-term differentiation options. The FDA‘s evolving guidance on obesity drug development, including its increasing emphasis on cardiovascular outcomes data, will shape which attributes ultimately determine market access and reimbursement for both programs.
“Novo Nordisk’s obesity portfolio presents both a bimolecular combination strategy (CagriSema) and a unimolecular co-agonist strategy (amycretin) that may compete or complement each other in the obesity market — a portfolio architecture that is unusual in the pharmaceutical industry.”
The patent intelligence picture supports a view of deliberate portfolio architecture rather than accidental duplication. Novo Nordisk has filed on SGLT2 inhibitor combinations with both the unimolecular GLP-1/amylin co-agonist (amycretin-type compounds) and with cagrilintide/semaglutide combinations, suggesting that triple-combination regimens are being actively explored as a third tier of the obesity portfolio. This is consistent with the broader trajectory of metabolic disease pharmacotherapy, where combination approaches targeting multiple pathways simultaneously have consistently outperformed monotherapy — a pattern documented across the diabetes, hypertension, and lipid-lowering fields and now being recapitulated in obesity drug development as reported in sources including EMA regulatory assessments and clinical literature.